Literature DB >> 16221996

Commentary: consensus statement on negative symptoms.

John Kane1.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16221996      PMCID： PMC2632202          DOI： 10.1093/schbul/sbj010

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  2 in total

1.  A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study.

Authors:  M Arato; R O'Connor; H Y Meltzer
Journal:  Int Clin Psychopharmacol       Date:  2002-09       Impact factor: 1.659

2.  Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.

Authors:  J M Kane; A Rifkin; M Woerner; G Reardon; S Sarantakos; D Schiebel; J Ramos-Lorenzi
Journal:  Arch Gen Psychiatry       Date:  1983-08
  2 in total
  1 in total

Review 1.  Persistent negative symptoms in schizophrenia: an overview.

Authors:  Robert W Buchanan
Journal:  Schizophr Bull       Date:  2006-11-10       Impact factor: 9.306
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.